bioAffinity Technologies, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
bioAffinity Technologies received written notice from Nasdaq on September 8, 2026, confirming regained compliance with Listing Rule 5550(a)(2) (minimum $1.00 bid price) and Listing Rule 5560(a) (rights/warrants requirements). The previously scheduled Nasdaq Hearings Panel hearing has been cancelled, and BIAF common stock and BIAFW warrants will continue trading on Nasdaq Capital Market, subject to ongoing compliance.
Why this rating
Averts delisting risk for micro-cap; material for survival but not growth. Compliance restoration is necessary condition, not driver of value creation.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.